Connect with us

Business

Five carmakers go on trial over emissions cheat claims

Published

on

Five carmakers go on trial over emissions cheat claims


Emer MoreauBusiness reporter

Getty Images A close up of a white car's exhaust pipe emitting fumesGetty Images

A major lawsuit against five leading carmakers accused of cheating on emissions tests is set to begin at the High Court on Monday.

The trial is the latest chapter of what has become known as the “dieselgate” scandal, with the companies facing allegations they used software to allow their cars to reduce emissions of harmful gases under test conditions.

Lawyers say the case is the largest class action in English and Welsh legal history, and could eventually involve 1.6 million car owners.

The five carmakers – Mercedes, Ford, Peugeot/Citroën, Renault and Nissan – all deny the accusations.

The five have been chosen by the court as lead defendants to be tried first as the case is so big.

Mercedes, Ford, Peugeot/Citroën, Renault and Nissan have been accused by 220,000 car owners of misleading them over emissions tests.

But depending on the outcome of this case, nine other carmakers are facing similar claims.

The dieselgate scandal first emerged in September 2015, when the US Environmental Protection Agency accused Volkswagen of installing software – known as “defeat devices” – on diesel cars to lower readings of the cars’ nitrogen oxide emissions.

In 2020, the High Court ruled that Volkswagen had used defeat devices in breach of European Union rules to pass emissions tests.

Volkswagen settled a class action out of court, paying £193m to 91,000 British motorists.

The company has so far paid out more than €32bn (£27.8bn) over the scandal, mostly in the US.

The High Court will decide whether systems installed in diesel cars by the five carmakers were designed to cheat clean air laws.

It is alleged the “defeat devices” allowed a car to identify when it was in a test scenario. It would then run its engine at below normal power and performance levels in order to record lower readings of nitrogen oxides.

Lawyers for the motorists will claim they were deceived about how environmentally friendly the vehicles were, and that the cars still on the road are continuing to emit dangerous levels of pollution.

Although the trial begins on Monday, a judgement is not expected until summer 2026. If the court finds against the carmakers, a further trial to determine levels of compensation is expected to begin in autumn 2026.

Martin Deigh of Leigh Day, which is one of the 22 law firms representing drivers, said: “A decade after the Dieselgate scandal first came to light, 1.6 million UK motorists now get their chance to establish at trial whether their vehicles contained technology designed to cheat emissions tests.”

He said that if the allegations against the car firms are upheld in court it “would demonstrate one of the most egregious breaches of corporate trust in modern times”.

“It would also mean that people across the UK have been breathing in far more harmful emissions from these vehicles than they were told about, potentially putting the health of millions at risk.”

The companies involved have said the claims against them are without merit.

A spokesperson for Mercedes said the mechanisms used in tests were “justifiable from a technical and legal standpoint”.

Renault and Stellantis, which owns Peugeot and Citroen, said the vehicles it sold were compliant with regulations at the time.

Ford said the claims had “no merit” and Nissan said it was “committed to compliance in all markets in which we operate”.



Source link

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Business

FDA official calls UniQure’s gene therapy a ‘failed’ treatment for Huntington’s disease

Published

on

FDA official calls UniQure’s gene therapy a ‘failed’ treatment for Huntington’s disease


Thomas Fuller | SOPA Images | Lightrocket | Getty Images

UniQure needs to run another study to prove that its gene therapy “actually helps people with Huntington’s disease,” a senior U.S. Food and Drug Administration official said on a call with reporters Thursday.

The official, who requested anonymity before discussing sensitive information, confirmed the agency has asked the company to run a placebo controlled trial of its treatment, which is administered directly into the brain. UniQure has said that type of study isn’t ethical because it would require putting people under general anesthesia for hours, a characterization the official disputed.

“So what is really going on? UniQure is the latest company to make a failed therapy for Huntington’s patients,” the official said. “They likely acknowledge or understand at some deep level that their trial failed years ago, and instead of doing the right thing and running the correct clinical study, UniQure is performing a distorted or manipulated comparison in the mind of FDA.”

The comments mark the latest development in a messy public spat between UniQure and the FDA, and as the agency comes under fire for a number of recent drug approval application rejections, including some where companies have accused it of going back on previous guidance. FDA Commissioner Marty Makary in an interview with CNBC’s Becky Quick last week seemingly criticized UniQure’s gene therapy for Huntington’s disease. Makary didn’t name UniQure but described its treatment.

UniQure then accused the FDA of reversing its stance that the company’s clinical trial data would be sufficient to seek approval. UniQure’s study used an outside database to measure how patients with Huntington’s disease might decline without treatment, known as an external control. UniQure has said it wouldn’t be feasible to run a true randomized, double-blind placebo-controlled study, considered the gold standard, because it wouldn’t be ethical to make people undergo a sham hours-long brain surgery.

The FDA official said the agency “never agreed to accept this distorted comparison” and the FDA “never makes such assurances.” Instead, the “FDA will always say, ‘Well, we have to see the data when we get it.'”

UniQure didn’t immediately comment.

The company’s stock rose more than 10% on Thursday and has fallen 58% this year as of Thursday afternoon.



Source link

Continue Reading

Business

US mortgage rates rise to 6% after three-week slide as oil-driven bond yields climb – The Times of India

Published

on

US mortgage rates rise to 6% after three-week slide as oil-driven bond yields climb – The Times of India


The average long-term US mortgage rate edged higher this week, ending a three-week decline as bond yields rose amid oil-price pressures linked to the war with Iran.The benchmark 30-year fixed mortgage rate increased to 6% from 5.98% last week, mortgage buyer Freddie Mac said on Thursday. A year ago, the average rate stood at 6.63%, AP reported.The modest uptick breaks a three-week slide in borrowing costs, with mortgage rates having hovered close to the 6% mark for most of this year. Last week’s average had marked the first time the rate dipped below 6% since September 2022, reaching its lowest level in nearly three and a half years.Mortgage rates are influenced by several factors, including the Federal Reserve’s interest-rate policy, investor expectations about inflation and economic growth, and movements in the bond market.They typically track the direction of the 10-year US Treasury yield, which lenders use as a benchmark for pricing home loans.The 10-year Treasury yield rose to 4.14% at midday Thursday, up from around 4% a week earlier.Treasury yields have moved higher in recent days as rising oil prices added fresh inflation concerns, potentially complicating the Federal Reserve’s plans to cut interest rates.



Source link

Continue Reading

Business

US stocks today: Dow tumbles 800 points, S&P 500 and Nasdaq slip as oil surges after Iran tanker strike – The Times of India

Published

on

US stocks today: Dow tumbles 800 points, S&P 500 and Nasdaq slip as oil surges after Iran tanker strike – The Times of India


US stock markets fell on Thursday as investors turned cautious after the previous session’s rally, while rising oil prices and geopolitical tensions weighed on sentiment.The Dow Jones Industrial Average dropped 801 points, or 1.6 per cent, dragged down by losses in stocks such as Caterpillar and Goldman Sachs. The S&P 500 declined 0.9 per cent, while the Nasdaq Composite fell 0.6 per cent.The selloff came as crude oil prices jumped to their highest level since June 2025 after Iran said it had struck an oil tanker with a missile. US West Texas Intermediate crude futures surged 6 per cent to trade above $79 per barrel, while international benchmark Brent crude futures rose about 3 per cent to more than $84 per barrel. Oil prices had stabilised in the previous trading session.Markets had rallied on Wednesday, supported by gains in technology and semiconductor stocks. The Dow had snapped a three-day losing streak, while the S&P 500 and Nasdaq Composite ended the session with solid gains.Despite the ongoing US-Israeli air campaign against Iran, US markets have performed relatively better than European and Asian counterparts this week, largely supported by a rebound in technology stocks that had been hit hard during February’s selloff.The tech-led recovery in the previous session helped the Nasdaq erase its weekly losses, putting the index on track to end the week in positive territory if gains hold through Friday.Investors remain concerned that prolonged disruption to shipping through the Strait of Hormuz — a key global energy corridor –could push oil prices higher and add to inflationary pressures through rising energy and shipping costs.Markets are particularly wary of crude prices moving towards $100 per barrel, which could complicate the Federal Reserve’s efforts to control inflation while considering interest-rate cuts.“For the past couple of years, bringing inflation down has been the Fed’s entire focus, and they were finally making progress. But if energy stays expensive, inflation could start climbing again and that would force the Fed to rethink its plans,” said Adam Sarhan, chief executive of 50 Park Investments, Reuters quoted.According to data compiled by LSEG, investors are increasingly expecting the Federal Reserve to delay a 25-basis-point interest rate cut to September from the previously anticipated July timeline.Among sectors, healthcare led declines on the S&P 500, dropping 1.6 per cent. The energy index, however, gained 0.7 per cent, with shares of ConocoPhillips and Valero Energy rising about 2 per cent each.The CBOE volatility index (VIX), widely seen as a gauge of market fear, rose 0.9 points to 22.08, reflecting cautious investor sentiment. The small-cap Russell 2000 index fell 1 per cent.Travel and tourism stocks, which are sensitive to fuel costs, were under pressure. Delta Air Lines slipped 3.3 per cent, while Royal Caribbean Cruises declined 0.6 per cent.On the other hand, some travel booking companies rallied sharply. Booking Holdings jumped 11 per cent and Expedia surged 8 per cent after a report by The Information said OpenAI was scaling back on-platform shopping checkout plans for ChatGPT, easing concerns about disruption to online marketplace businesses.Chip stocks showed mixed performance. Nvidia edged down 0.3 per cent, while Marvell Technology gained 1.3 per cent.Shares of Broadcom rose 2.9 per cent after the chip designer projected that its artificial intelligence chip revenue could exceed $100 billion next year.Elsewhere, Trade Desk surged 22.5 per cent following a report that OpenAI had held early discussions with the advertising technology company regarding the sale of advertisements.Economic data released on Thursday showed the number of Americans filing new applications for unemployment benefits remained unchanged last week.Investors are also awaiting remarks from Federal Reserve Vice Chair Michelle Bowman later in the day, ahead of the closely watched non-farm payrolls report due on Friday.On the New York Stock Exchange, declining stocks outnumbered advancers by a ratio of 2.48-to-1, while on the Nasdaq the ratio stood at 1.63-to-1.The S&P 500 recorded four new 52-week highs and two new lows, while the Nasdaq Composite registered 17 new highs and 33 new lows.



Source link

Continue Reading

Trending